Company intelligence / Profile preview

Encora Therapeutics

Boston, Massachusetts, United Statesencoratherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company’s wrist-worn vibratory stimulation wearable demonstrated safety and efficacy in reducing upper limb tremors in essential tremor patients. The ULTRE study was a double-blind, randomized, sham-controlled cross-over trial with robust inclusion criteria. Their abstract was awarded “Abstract of Distinction” at the AAN Annual Meeting in April 2025. The technology leverages personalized vibration paradigms to provide non-invasive symptom relief. No commercial launch yet as of June 2025. Breakthrough Device status from FDA supports accelerated regulatory review.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Encora Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Encora Therapeutics.

Explore the full profile